Cystic fibrosis gene therapy with recombinant adenovirus: A long way to go;Therapie genique somatique de la mucoviscidose par adenovirus recombinants: Les debuts d'un long parcours

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 5, 1997, Pages 148-157

  Rochat, T ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; TRANSMEMBRANE CONDUCTANCE REGULATOR; RECOMBINANT PROTEIN;

ADENOVIRUS; CONFERENCE PAPER; CYSTIC FIBROSIS; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNITY; ANIMAL; BRONCHUS; EPITHELIUM; GENE TARGETING; GENE VECTOR; GENETICS; IMMUNOLOGY; METHODOLOGY; PHYSIOLOGY; REVIEW;

ADENOVIRIDAE; ANIMALS; BRONCHI; CYSTIC FIBROSIS; EPITHELIUM; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIPOSOMES; RECOMBINANT PROTEINS;

EID: 0031065518     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Riordan JR, Rommens JM, Kerem BT, Alon N, Rozmahel R et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
2. Koch C, Høiby N: Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065-1069.
3. Elborn JS, Shale DJ, Britton JR: Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46: 881-885.
4. Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-779.
5. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER et al.: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
6. Welsh MJ, Smith AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-1254.
7. Chinet TC, Fullton JM, Yankaskas JR, Boucher RC, Stutts MJ: Mechanism of sodium hyperabsorption in cultured cystic fibrosis nasal epithelium: a patch-clamp study. Am J Physiol 1994; 266: C1061-C1068.
8. Boucher RC: Human airway ion transport. Part one. Am J Respir Crit Care Med 1994; 150: 271-281.
9. Boucher RC: Human airway ion transport. Part two. Am J Respir Crit Care Med 1994; 150: 581-593.
10. Zar H, Saiman L, Quittel L, Prince AS: The binding of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients with various mutations in CFTR. J Pediatr 1995; 126: 230-233.
11. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG et al.: Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271: 64-67.
12. Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-236.
13. Rosenfeld MA, Rosenfeld SJ, Danel C, Banks TC, Crystal RG: Increasing expression of the normal human CFTR cDNA in cystic fibrosis epithelial cells results in a progressive increase in the level of CFTR protein expression, but a limit on the level of cAMP-stimulated chloride secretion. Hum Gene Ther 1994; 5: 1121-1129.
14. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R et al.: In vivo gene delivery and stable transduction of nondiving cells by a lentiviral vector. Science 1996; 272: 263-267.
15. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R et al.: Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613-10617.
16. Caplen NJ, Alton EWFW, Middleton PG, Dorin JR, Stevenson BJ et al.: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Medicine 1995; 1: 39-46.
17. Caplen NJ, Kinrade E, Sorgi F, Gao X, Gruenert D et al.: In vitro liposome-mediated DNA transfection of epithelial cell lines using cationic liposome DC-Chol/DOPE. Gene Ther 1995; 2: 603-613.
18. Ferkol T, Kaetzel CS, Davis PB: Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J Clin Invest 1993; 92: 2394-2400.
19. Top FH: Control of adenovirus acute respiratory disease in US Army trainees. Yale J Biol Med 1975; 48: 185-195.
20. Zabner J, Couture LA, Smith AE, Welsh MJ: Correction of cAMP-stimulated fluid secretion in cystic fibrosis airway epithelia: efficiency of adenovirus-mediated gene transfer in vitro. Hum Gene Ther 1994; 5: 585-593.
21. Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN et al.: Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371: 802-806.
22. Crystal RG, McElvaney NG, Rosenfeld MA, Chu C-S, Mastrangeli A et al.: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 1994; 8: 42-51.
23. Puchelle E, Gaillard D, Ploton D, Hinnrasky J, Fuchey C et al.: Differential localization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis airway epithelium. Am J Respir Cell Mol Biol 1992; 7: 485-491.
24. McElvaney NG, Crystal RG: IL-6 release associated with airway administration of human CFTR cDNA adenovirus vector. Nature Med 1995; 1: 182-184.
25. Bellon G, Calmard L, Thouvenot D, Jagneaux V, Poitevin F et al.: Aerosol administration to cystic fibrosis patients of a replication defective adenovirus expressing the CFTR gene (Ad. CFTR). Pediatr Pulmonol 1995; (Suppl. 12 [abstr.]): 228.
26. Chinet TC: Use of the in vivo nasal transepithelial potential difference to evaluate efficacy in CF gene therapy phase I trials. Eur Respir J 1994; 7: 1917-1920.
27. Middleton PG, Geddes DM, Alton EWFW: Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994; 7: 2050-2056.
28. Knowles MR, Paradiso AM, Boucher RC: In vivo nasal potential difference: techniques and protocol for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445-455.
29. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
30. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP et al.: Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.
31. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL et al.: A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Eng J Med 1995; 333: 823-831.
32. Hay JG, McElvaney NG, Herena J, Crystal RG: Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995; 6: 1487-1496.
33. Pickles RJ, Barker PM, Ye H, Boucher RC: Efficient adenovirus-mediated gene transfer to basal but not columnar cells of cartilaginous airway epithelia. Hum Gene Ther 1996; 7: 921-931.
34. Goldman MJ, Wilson JM: Expression of avb5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol 1995; 69: 5951-5958.
35. Huang S, Endo RI, Nemerow GR: Upregulation of integrins avb3 and avb5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257-2263.
36. Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus base to new receptor through replacement of ist RGD motif with other receptor-specific peptide motifs. Gene Ther 1995; 2: 750-756.
37. Yang Y, Nunes FA, Berencsi K, Gönczöl E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenovirus improves the prospect for gene therapy in cystic fibrosis. Nature Genet 1994; 7: 362-369.
38. Yang Y, Trinchieri G, Wilson JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
39. Yang Y, Li Q, Ertl HCJ, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J Virol 1995; 69: 2004-2015.
40. Yang Y, Wilson JM: Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155: 2564-2570.
41. VanGinkel FW, Liu C, Simecka JW, Dong J-Y, Greenway T et al.: Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum Gene Ther 1995; 6: 895-903.
42. McCoy RD, Davidson BL, Roessler BJ, Huffnagle GB, Janich SL et al.: Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Human Gene Ther 1995; 6: 1553-1560.
43. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnell BC: Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therapy 1994; 1: 192-200.
44. Tripathy SK, Black HB, Goldwasser E, Leiden JM: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
45. Wilson C, Kay MA: Immunomodulation to enhance gene therapy. Nature Med 1995; 1: 887-889.
46. Kay MA, Holterman A, Meuse L, Gown A, Ochs HD et al.: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genet 1995; 11: 191-197.
47. Hyde SC, Gill DR, Higgins CF, Trezise AEO, MacVinish LJ et al.: Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 1993; 362: 250-255.
48. Gao X, Huang L: Cationic liposome-mediated gene transfer. Gene Ther 1995; 2: 710-722.
49. Anthonisen N: Design of a clinical trial to test a treatment of the underlying cause of emphysema. Ann NY Acad Sci 1991; 624 (Suppl.): 31-34.
50. Stern M, Munkonge FM, Caplen NJ, Sorgi F, Huang L et al.: Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects. Gene Ther 1995; 2: 766-774.
51. Renier M, Tamanini A, Nicolis E, Rolfini R, Imler J-L et al.: Use of a membrane potential-sensitive probe to assess biological expression of the cystic fibrosis transmembrane conductance regulator. Hum Gene Ther 1995; 6: 1275-1283.